News

Finfeed – Proteomics awarded vital CE Mark registration for PromarkerD

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, has secured CE Mark registration for its PromarkerD Immunoassay kit as an IVD medical device (in vitro diagnostic).

“This is a key market for Proteomics as the company’s business model is centred on the commercialisation of its world-leading test for diabetic kidney disease, PromarkerD.

Article: Proteomics awarded vital CE Mark registration for PromarkerD

Subscribe
  • This field is for validation purposes and should be left unchanged.